Inversago Pharma reeled in a $7 million series A round to move a suite of next-generation cannabinoid receptor-1 (CB1) blockers into the clinic. Read More
The post Canadian cannabinoid biotech Inversago looks to the clinic appeared first on Dagga Magazine.